In the tumor microenvironment (TME), the struggle for survival is fundamentally a competition for resources. Recent research has shifted from viewing tumors as passive genetic mutants to active metabolic engineers. By hijacking nutrient pathways and secreting metabolic byproducts, tumors create a "metabolic shield" that simultaneously fuels their own growth and paralyzes the host’s immune response.
Nutrient Competition and Starvation
The most direct way a tumor suppresses immunity is by consuming the very nutrients that T cells need to function. T cells require significant amounts of glucose and amino acids to transform from a resting state into active "killers." Tumors exploit this by overexpressing transporters like SLC2A3, which Wei Jiang et al. found not only fuels the tumor but actively triggers ferroptosis—a form of programmed cell death—in CD8+ T cells by depriving them of essential metabolic balance in SLC2A3 promotes head and neck squamous cancer developing through negatively regulating CD8+ T cell in tumor microenvironment.
Beyond glucose, tumors use enzymes like IDO1 to deplete tryptophan, an essential amino acid for T cell survival. As Yao Zhou et al. discuss in Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy, this metabolic modulation starves infiltrating immune cells, rendering the TME hostile to natural defenses.
Oncometabolites as Signaling Molecules
Tumors do not just consume; they also produce. Metabolic byproducts, once considered mere waste, are now recognized as potent signaling molecules that reprogram immune cells. Lactate is a primary example. Deblina Raychaudhuri et al. demonstrated in Lactate Induces Pro-tumor Reprogramming in Intratumoral Plasmacytoid Dendritic Cells that lactate hijacks the metabolism of dendritic cells, converting them from anti-tumor warriors into immunosuppressive allies that promote regulatory T cell expansion.
Similarly, Xiaofeng Li et al. identified the lactate receptor GPR81 as a master switch in GPR81-mediated reprogramming of glucose metabolism contributes to the immune landscape in breast cancer. By activating the Hippo-YAP pathway, GPR81 drives a metabolic shift that recruits suppressive immune cells while excluding cytotoxic T cells. Even the loss of housekeeping enzymes can be weaponized; the authors of MTAP loss correlates with an immunosuppressive profile in GBM and its substrate MTA stimulates alternative macrophage polarization show that the resulting accumulation of the substrate MTA stimulates macrophages to adopt a pro-tumor "M2" profile.
Checkpoint-Mediated Metabolic Rewiring
Immune checkpoints like PD-1 are traditionally viewed as signaling brakes, but they also function as metabolic switches. Nikolaos Patsoukis et al. revealed in PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation that PD-1 forces T cells to abandon glycolysis in favor of fatty acid oxidation. This metabolic shift pushes T cells into a state of permanent exhaustion and quiescence, explaining why they persist in tumors without attacking them.
This metabolic-immune circuitry is often driven by central hubs like CCRK and mTORC1. Hanyong Sun et al. showed in An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma how these pathways connect systemic inflammation (such as that caused by obesity) to the recruitment of immune-suppressing cells, effectively synchronizing the tumor's energy needs with its evasion strategies.
Organelle and Lipid Regulation
The internal machinery of the cell—specifically mitochondria and lipid synthesis pathways—plays a critical role in this crosstalk. Mitochondrial proteins like NDUFAF6 and the SLC25A family act as gatekeepers. Baohong Jiang et al. found in Impact of NDUFAF6 on breast cancer prognosis: linking mitochondrial regulation to immune response and PD-L1 expression that mitochondrial regulation directly influences the expression of PD-L1, the primary shield against T cell attack.
Lipid metabolism is equally vital. H H He et al. identified ACACA as a master regulator of fatty acid synthesis that facilitates immune evasion across multiple cancers in Integrated single-cell and bulk RNA sequencing analysis reveals ACACA as a potential prognostic and immunotherapeutic biomarker across cancers. Conversely, restoring proper lipid flux can reverse these effects. Guangsi He et al. demonstrated in Aquaglyceroporin-7 ameliorates sorafenib resistance and immune evasion in hepatocellular carcinoma through inhibition of lipid accumulation that inhibiting lipid accumulation can "re-sensitize" tumors to therapy and transform the TME from immunosuppressive to immune-active.
Therapeutic Implications of Metabolic Reversal
Understanding these mechanisms opens new avenues for treatment by repurposing metabolic drugs. Dianyun Ren et al. showed in Metformin activates the STING/IRF3/IFN-β pathway by inhibiting AKT phosphorylation in pancreatic cancer. that the anti-diabetes drug metformin can enhance immune infiltration by targeting metabolic signaling. Similarly, Henrik H. Hansen et al. found that semaglutide reduces tumor burden in Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis, likely through systemic metabolic restoration.
By targeting the metabolic vulnerabilities of the tumor—such as blocking PPARγ signaling to "inflame" the TME, as proposed by Zhewen Xiong in Targeting hepatoma-intrinsic pparγ signaling overcomes immune checkpoint therapy resistance by inflaming the tumor microenvironment—researchers aim to strip away the tumor's metabolic shield, finally allowing the immune system to finish its job.
Key Foundational Work
An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma (2018) — contributed 1 concept elements to this direction.
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation (2015) — contributed 1 concept elements to this direction.